Trial intelligence / Profile preview

Vyvanse in Binge Eating Disorder

NCT01718509Phase 3Completed

Sponsor
Takeda
Start
Nov 2012
Primary completion
Sep 2013
Modality
Small Molecules
Countries
2
01

Overview

A Phase 3 trial of lisdexamfetamine in binge eating disorder (BED), sponsored by Takeda. Started Nov 2012; status: completed.

02

Drugs

lisdexamfetamine
03

Conditions

binge eating disorder (BED)

Beyond the preview

Go deeper on NCT01718509.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on NCT01718509.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call